Hospitals routinely underestimate the true cost of thrombectomy because they focus on device price instead of the full episode of care. This article argues for a broader, “total cost” view that captures all direct and indirect drivers of financial performance around clot-removal procedures.
Why “total cost” matters
Most thrombectomy cost discussions center on device list price, yet materials are only one component of overall spend. When you factor in staff time, room utilization, ICU and floor days, labs, drugs, readmissions, and post‑procedure complications, the picture of value can change dramatically. A strategy that looks expensive on the shelf may be more affordable over the full patient journey if it shortens procedures, reduces complications, and avoids repeat interventions.
Key economic drivers highlighted
The new whitepaper breaks thrombectomy economics into several major levers.
- Reimbursement and margin: Payer rates, especially Medicare, may not fully cover the real cost of thrombectomy, so efficiency gains directly protect hospital margins.
- Procedural time and staffing: Longer cases mean more physician, anesthesia, and nursing time plus higher opportunity cost for busy labs.
- Device and disposables: Aspiration and mechanical systems can have high upfront material costs that often represent the majority of per‑case expense.
- Length of stay: ICU and ward days quickly eclipse the cost of most single-use devices when complications or slow recovery extend hospitalization.
- Complications and reinterventions: Bleeding, repeat procedures, and readmissions drive large downstream costs that rarely show up in basic supply-line analyses.
Read the full paper here: Understanding Total Cost of Procedures
